세계 복막투석 장비 시장 – 2023-2030

Overview
Global Peritoneal Dialysis Equipment Market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
End-stage Renal Disease (ESRD) or severe kidney failure is treated with peritoneal dialysis (PD) technology. When the kidneys are no longer working effectively, peritoneal dialysis is a type of renal replacement therapy that aids in removing waste and extra fluid from the body. The patient's preferences, way of life, and medical requirements determine whether manual CAPD or automatic APD should be used. Several times a day, CAPD requires human exchanges of dialysis fluid, whereas APD employs a machine for nocturnal exchanges.
The effectiveness, safety, and usability of peritoneal dialysis apparatus have been enhanced by technological advances. As a result of these technical developments, more patients are opting for peritoneal dialysis as a form of treatment. The need for dialysis treatments, particularly peritoneal dialysis, has increased due to an aging population's greater susceptibility to kidney-related disorders.
Dynamics
Increasing Advantages of Peritoneal Dialysis
As per the article published in Frontiers in Physiology in 2023, hemodialysis (HD) is not always an appropriate therapy option for those with kidney failure or end-stage kidney disease. The adoption of peritoneal dialysis, which has been around for more than 40 years, has varied greatly globally for several reasons. According to the Global Kidney Health Atlas, 38.1 per million individuals (pmp) on average undergo chronic PD treatment, which is significantly less than the 298.4 pmp estimated global prevalence of HD.
Peritoneal dialysis has a number of benefits, including better blood pressure management, better renal function maintenance, and a more flexible and autonomous treatment plan that gives patients more autonomy. Some patients and providers may find PD to be a desirable alternative because it can have lower expenses for both patients and the healthcare system.
The Rising Prevalence of Chronic Kidney Disease
More than 800 million people worldwide—more than 10% of the overall population—have chronic kidney disease, which is a degenerative disorder. Persons with diabetes mellitus, hypertension, elderly persons, women, and people of color are more likely to develop chronic kidney disease. Because they are least prepared to handle its effects, low- and middle-income countries bear a disproportionately heavy burden from chronic kidney disease.
According to the Centers for Disease Control and Prevention, approximately 35.5 million US adults, or 14%, are believed to have CKD.† Up to 90% of persons with CKD are unaware of their condition. One in three adults with severe CKD is unaware of their condition. People with CKD are more likely to be over 65 (34%) than between 45 and 64 (12%) or between 18 and 44 (6%). Women (14%) have CKD at a somewhat higher rate than males (12%). Compared to non-Hispanic Asian (14%) and non-Hispanic White (12%) adults, non-Hispanic Black adults (20%) had a higher prevalence of CKD.
Increased efforts for better prevention and treatment should be made as a result of the large number of afflicted people and the serious negative effects of chronic renal disease. Results in increasing demand for peritoneal dialysis equipment in the market.
Limited Awareness of Peritoneal Dialysis
The lack of knowledge of peritoneal dialysis (PD) as a treatment option for end-stage renal disease (ESRD) among patients and healthcare providers is a serious problem that can have numerous effects. It is possible that patients with ESRD are unaware that PD is a therapy option. Due to a lack of knowledge, patients may postpone starting their dialysis treatment or perhaps decide against it altogether. As a result, people might pass up the chance to properly control their disease.
Patients may believe they have few options for treating their renal failure if they are unaware of PD. Because of this, more patients may choose in-center hemodialysis when they could have opted for PD had they known about its advantages.
Infection Risks
Catheter must be inserted into the abdomen during peritoneal dialysis (PD), and doing so increases the risk of infection. An abdominal wall incision is made during the initial PD catheter placement surgery, and the catheter is then introduced into the peritoneal cavity. Like with any operation, there is a chance that this technique will spread bacteria.
The patient's peritoneal dialysis therapy may last months or even years, during which time the catheter is left in place. Bacterial invasion into the peritoneal cavity is more likely the longer the catheter is in place.
Segment Analysis
The global peritoneal dialysis equipment market is segmented based on product, treatment type, end-users and region.
The Automated Peritoneal Dialysis (APD) segment accounted for approximately 45.6% of the market share
APD is a form of PD that involves employing a dialysis machine to deliver and drain the dialysate automatically and with a minimum of human involvement. APD exchanges can be completed overnight while you sleep and normally take between 8 and 12 hours. One of the kidney functions that dialysis treatment substitutes is ultrafiltration, which is the evacuation of fluid from the patient's body. Ultrafiltration is used in peritoneal dialysis (PD) to remove fluid via the peritoneal membrane.
In some cases, APD may have a stronger ultrafiltration effect, allowing for more fluid to be evacuated during each exchange and lowering edema brought on by an excess of fluid. Patients would only need to attach and disconnect their catheter from the APD machine once per day because APD exchange is typically performed overnight. Patients would then need to connect and disconnect their catheter from the dialysate bags numerous times during the day, which can dramatically increase their risk of infection. CAPD exchanges are typically performed three to four times throughout the day.
Geographical Penetration
North America segment accounted for approximately 45.7% of the market share
North America has been a dominant force in the global peritoneal dialysis equipment market. It has long proven difficult to administer kidney dialysis to little, vulnerable neonates because the majority of dialysis devices are made for adults. However, the Children's Hospital of Los Angeles is now able to offer this life-saving treatment to infants thanks to a unique system designed especially for them.
The technology, known as the Carpediem Cardio-Renal young Dialysis Machine, is recognized by the Food and Drug Administration and offers young patients as small as 2.5 kilos (about 5 pounds) with continuous renal replacement therapy.
For instance, in November 2022, the nation's top manufacturer of dialysis equipment, Fresenius Medical Care North America (FMCNA), announced that its Liberty Select Cycler has received FDA 510(k) approval, enabling remote therapy management using the Kinexus Therapy Management Platform. The goal of this improvement is to improve the home therapy experience for PD patients and medical professionals.
Clinicians for home dialysis are helped by Liberty Select and Kinexus to make crucial decisions based on timely, reliable treatment data summaries. To help evaluate the efficacy of the program, Care Teams will also have access to up to 90 days' worth of treatment data history. The dialysis clinician can modify the therapy plan as necessary to provide quick, data-driven interventions. Market-available Liberty Select cyclers can be upgraded to support remote therap management.

COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global peritoneal dialysis equipment market. Since patients getting in-center hemodialysis frequently have comorbid conditions that place them at an increased risk for serious illness, COVID-19 raised questions about the safety of these individuals. As a result, peritoneal dialysis and other home-based dialysis techniques gained popularity. To lessen virus exposure, a lot of patients and medical professionals looked for methods that let patients practice dialysis at home.
Due to worries about COVID-19, some patients may have put off starting peritoneal dialysis or switching to it. The adoption of peritoneal dialysis was dependent on how carefully healthcare professionals and patients weighed the risks and advantages of various treatment alternatives.
Key Developments
• In June 2023, AWAK Technologies (AWAK) and Singapore General Hospital (SGH) stated the beginning of a pre-pivotal clinical trial with the enrollment of their first patient to examine the safety and effectiveness of an upgraded Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device.
Competitive Landscape
The major global players in the market include AWAK Technologies, Baxter International Inc., Medtronic plc, Fresenius Medical Care North America, Terumo Corporation, Utah Medical Products, Inc., Polymedicure, Angiplast, Merit Medical Systems, and Newsol Technologies Inc.
Why Purchase the Report?
• To visualize the global peritoneal dialysis equipment market segmentation based on product, treatment type, end-users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of peritoneal dialysis equipment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global peritoneal dialysis equipment market report would provide approximately 61 tables, 54 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies